SCHEDULE 13D/A
SCHEDULE 13D/ASchedule 13D ownership disclosure
BRIDGEBIO PHARMA INC
Common Stock, par value $0.001 per share · CUSIP: 10806X102
Event date: 2025-06-27
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- VIKING GLOBAL INVESTORS LPReported CIK 0001103804
Shares: 18,602,920 · Class: 9.8%
- VIKING GLOBAL PERFORMANCE LLCReported CIK 0001132625
Shares: 339,695 · Class: 0.2%
- Viking Global Equities II LPReported CIK 0001413378
Shares: 6,794 · Class: 0%
- Viking Global Equities Master Ltd.Reported CIK 0001759530
Shares: 332,901 · Class: 0.2%
- Viking Long Fund GP LLCReported CIK 0001621607
Shares: 118,214 · Class: 0.1%
- Viking Long Fund Master Ltd.Reported CIK 0001621596
Shares: 118,214 · Class: 0.1%
- Viking Global Opportunities Parent GP LLCReported CIK 0001886738
Shares: 18,145,011 · Class: 9.6%
- Viking Global Opportunities GP LLCReported CIK 0001629476
Shares: 18,145,011 · Class: 9.6%
- Viking Global Opportunities Portfolio GP LLCReported CIK 0001629472
Shares: 18,145,011 · Class: 9.6%
- Viking Global Opportunities Illiquid Investments Sub-Master LPReported CIK 0001629482
Shares: 18,089,980 · Class: 9.5%
- Viking Global Opportunities Liquid Portfolio Sub-Master LPReported CIK 0001629483
Shares: 55,031 · Class: 0.03%
- HALVORSEN OLE ANDREASReported CIK 0001133006
Shares: 18,602,920 · Class: 9.8%
- Ott David C.Reported CIK 0001621842
Shares: 18,602,920 · Class: 9.8%
- Shabet Rose SharonReported CIK 0001711393
Shares: 18,602,920 · Class: 9.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000905148-25-002298
- Form type
- SCHEDULE 13D/A
- Filer
- BridgeBio Pharma, Inc.
- CIK
- CIK 1743881
- Filed
- Jul 01, 2025
- Reporting period
- Jun 27, 2025
- Description
- Schedule 13D beneficial ownership